Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy (Q43985166)

28 November 2017

Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy (English)

1 reference

28 November 2017

1

1 reference

28 November 2017

Esteban Domingo Solans

7

1 reference

28 November 2017

Mas A

2

1 reference

28 November 2017

Gómez-Mariano G

3

1 reference

28 November 2017

Altisent C

4

1 reference

28 November 2017

Menéndez-Arias L

5

1 reference

28 November 2017

Soriano V

6

1 reference

28 November 2017

1 January 2000

1 reference

28 November 2017

1 reference

28 November 2017

66

1 reference

28 November 2017

13-26

1 reference

28 November 2017

1

1 reference

Virus dynamics and drug therapy

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Rapid and simple method for purification of nucleic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

The red queen reigns in the kingdom of RNA viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Nucleotide sequence heterogeneity of an RNA phage population.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Rates of spontaneous mutation among RNA viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Rapid selection of genetic and antigenic variants of foot-and-mouth disease virus during persistence in cattle

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Toward HIV eradication or remission: the tasks ahead.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Evolution of multiple genome mutations during long-term persistent infection by vesicular stomatitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Rapid evolution of RNA genomes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Mechanisms of retroviral mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Reproducible nonlinear population dynamics and critical points during replicative competitions of RNA virus quasispecies.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

The frequency of resistant mutant virus before antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Resistance, drug failure, and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Extensive variation of human immunodeficiency virus type-1 in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Stable rearrangements of the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-1702%2899%2900120-3

7 January 2021

10.1016/S0168-1702(99)00120-3

Identifiers

DOI

1 reference

release_s2szeg6xuvcdpejpgqzgongnee

28 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/s2szeg6xuvcdpejpgqzgongnee

24 November 2022

mapped directly with Wikidata item

1 reference